3 results
Approved WMOCompleted
To evaluate BlueWind Medical RENOVATM System safety and performance in OAB patients for extended FU period of 36 months.
Approved WMOWill not start
Primary ObjectiveTo evaluate the preliminary safety and tolerability and the preliminary efficacy of cobimetinib administered as single agent (Arm A), cobimetinib + venetoclax (Arm B), and cobimetinib + venetoclax + atezolizumab (Arm C)Secondary…
Approved WMOPending
The primary objective is to assess if there are any differences in terms of Bone Mineral Density between patients receiving the BICON-PLUS NT with an alumina reduced device surface (study group) and a group of patients receiving the BICON-PLUS with…